Organigram has begun looking for a new CEO, as current CEO Beena Goldenberg will step down at the end of Organigram’s current fiscal year in September. 

Goldenberg will be leaving the company four years after she first became CEO in September 2021, overseeing Organigram’s transformation from a cannabis company with $80 million in net revenue to becoming a market share leader in Canada with over $250 million in net revenue. 

Under her leadership, the company completed an expansion of its facility in Moncton, New Brunswick, doubling cultivation capacity, as well as three strategic acquisitions that led to Organigram’s number one share positions in vapes, hash, and pre-rolls in Canada, including the recent acquisition of Motif.

Goldenberg also oversaw Organigram’s international expansion with export sales into Germany, the UK, and Australia. The latest acquisition of Collective Project, announced on April 1, 2025, signalled the first revenue recognized by Organigram from the US market.

Before her time with Organigram, Goldenberg was CEO of Supreme Cannabis Co. from April 2020 to September 2021. 

“After five incredible years in the cannabis industry, serving as CEO of Supreme Cannabis Company and Organigram Global, I have decided it is time to move on to my next chapter,” said Goldenberg in a press release. “Reflecting on my journey, I am extremely proud of what has been accomplished in this nascent industry. The challenges we faced and the successes we achieved underscore the immense potential that still lies ahead for the cannabis industry.”

Organigram Global Inc. brought in $42.5 million in net income for their most recent fiscal report covering the three months ending March 31, 2025 (Q2 2025) from $102.8 million in gross revenue and $65.6 million in net revenue.

Net income for the Moncton-based producer increased 163.8% year-over-year compared to Q2 2024’s net loss of $27.1 million and an increase from the $23 million net loss in Q1 2025. 

In February 2025, Organigram also closed on the final $41.5 million tranche of funding from British American Tobacco’s Jupiter Pool funds, helping strengthen the company’s balance sheet and fuel international expansion goals.

​​In 2023, Organigram announced that most of a $124.6 million investment from British American Tobacco (BAT) would be allocated to create a strategic investment pool named Jupiter, focusing on emerging cannabis opportunities, including geographic expansion. In 2021, the deal was first announced as a C$221 million strategic investment and has continued to evolve over the years.

“On behalf of the Board, I express our gratitude to Beena for her exceptional leadership and commitment to Organigram,” said Peter Amirault, Chairman of the Board, Organigram. “Beena has been instrumental in positioning Organigram as a market leader in Canada and poised for global expansion. She has created an excellent base for both domestic and international growth for Organigram. And therefore, the Company is well positioned to take advantage of this significant opportunity. The Board remains confident in the Company’s strategic direction as well as its leadership team, and we are committed to appointing a new CEO who will continue to drive our vision forward, ensuring that the Company remains at the forefront of cannabis innovation and growth.”

The Board is in the process of initiating a comprehensive CEO selection process to identify a candidate with the right mix of skills and experience to lead the company in its next chapter of growth.

 “It has been an honour to lead Organigram Global through this critical chapter in our evolution, and I am grateful to have had the privilege of working with so many talented and passionate people who have played a significant role in our collective growth and achievements,” added Goldenberg. “Over the next four months I will remain focused on driving Organigram’s growth and profitability while supporting the smooth onboarding of a new CEO to lead the Company forward in its next phase of growth.”

Related Articles

Organigram reports spike in sales, revenue from Motif acquisition 

May 12, 2025

Organigram enters US market through acquisition of Collective Project Beverages

April 1, 2025

Organigram closes on final round of funding from British American Tobacco 

March 3, 2025